Delayed kallikrein treatment starting at 8 h, 24 h, and 36 h significantly raised the number of BrdU-positive cells compared with the MCAO group suggesting that delayed kallikrein protection against stroke was associated with cell proliferation enhancement. The gene discussed is KLK4; the disease is stroke disorder.